Iovance Biotherapeutics, Inc.

IOVA

Find Out if You Qualify for a Financial Reward by filling out the form below.

Iovance Biotherapeutics, Inc. Form












Stock Fraud Law Center does not share your information with others. There is no cost or obligation for you to submit.

Investigation Details

On December 27, 2023, Iovance announced that, on December 22, 2023, the U.S. Food and Drug Administration (“FDA”) had placed a clinical hold on the Company’s IOV-LUN-202 trial, which was investigating the Iovance’s lead product candidate for the treatment of metastatic non-small cell lung cancer. Iovance advised that the FDA’s decision to place the clinical hold was “in response to a recently reported Grade 5 (fatal) serious adverse event potentially related to the non-myeloablative lymphodepletion pre-conditioning regimen.”

On this news, Iovance’s stock price fell 18.67% to close at $7.23 per share on December 27, 2023.

Active Cases

Ticker Symbol Company Name Join Deadline Join
UPS United Parcel Service, Inc. December 09, 2024 Join
EW Edwards Lifesciences Corporation December 13, 2024 Join
TD The Toronto-Dominion Bank December 23, 2024 Join
WOLF Wolfspeed, Inc. January 17, 2025 Join